PMID- 37232831
OWN - NLM
STAT- MEDLINE
DCOM- 20230529
LR  - 20230602
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 30
IP  - 5
DP  - 2023 May 12
TI  - The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH 
      Wild-Type Glioblastoma.
PG  - 4946-4956
LID - 10.3390/curroncol30050373 [doi]
AB  - Introduction: Glioblastoma (GBM) patients have a 20-30 incidence of venous 
      thromboembolic events. EGFR is a widely used prognostic marker for many cancers. 
      Recent lung cancer studies have described relationships between EGFR 
      amplification and an increased incidence of thromboembolic complications. We aim 
      to explore this relationship in glioblastoma patients. Methods: Two hundred 
      ninety-three consecutive patients with IDH wild-type GBM were included in the 
      analysis. The amplification status of EGFR was measured using fluorescence in 
      situ hybridization (FISH). Centromere 7 (CEP7) expression was recorded to 
      calculate the EGFR-to-CEP7 ratio. All data were collected retrospectively through 
      chart review. Molecular data were obtained through the surgical pathology report 
      at the time of biopsy. Results: There were 112 subjects who were EGFR-amplified 
      (38.2%) and 181 who were non-amplified (61.8%). EGFR amplification status was not 
      significantly correlated with VTE risk overall (p = 0.2001). There was no 
      statistically significant association between VTE and EGFR status after 
      controlling for Bevacizumab therapy (p = 0.1626). EGFR non-amplified status was 
      associated with an increased VTE risk in subjects greater than 60 years of age (p 
      = 0.048). Conclusions: There was no significant difference in occurrence of VTE 
      in patients with glioblastoma, regardless of EGFR amplification status. Patients 
      older than 60 years of age with EGFR amplification experienced a lower rate of 
      VTE, contrary to some reports on non-small-cell lung cancer linking EGFR 
      amplification to VTE risk.
FAU - Kaye, Brandon
AU  - Kaye B
AUID- ORCID: 0000-0002-2047-3396
AD  - Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, 
      Fort Lauderdale, FL 33328, USA.
FAU - Ali, Assad
AU  - Ali A
AD  - Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA.
FAU - Correa Bastianon Santiago, Raphael Augusto
AU  - Correa Bastianon Santiago RA
AUID- ORCID: 0000-0003-3690-8275
AD  - Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA.
FAU - Ibrahim, Bilal
AU  - Ibrahim B
AUID- ORCID: 0000-0002-1235-1233
AD  - Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA.
FAU - Isidor, Julio
AU  - Isidor J
AD  - Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA.
FAU - Awad, Hany
AU  - Awad H
AD  - Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA.
FAU - Sabahi, Mohammadmahdi
AU  - Sabahi M
AD  - Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA.
FAU - Obrzut, Michal
AU  - Obrzut M
AD  - Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA.
FAU - Adada, Badih
AU  - Adada B
AD  - Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA.
FAU - Ranjan, Surabhi
AU  - Ranjan S
AD  - Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA.
FAU - Borghei-Razavi, Hamid
AU  - Borghei-Razavi H
AD  - Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA.
LA  - eng
PT  - Journal Article
DEP - 20230512
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (EGFR protein, human)
SB  - IM
MH  - Humans
MH  - ErbB Receptors/genetics/metabolism
MH  - Retrospective Studies
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - *Glioblastoma/complications/genetics/metabolism
MH  - *Venous Thromboembolism/genetics
MH  - *Lung Neoplasms
MH  - In Situ Hybridization, Fluorescence
MH  - Prognosis
PMC - PMC10217574
OTO - NOTNLM
OT  - IDH wild-type
OT  - epidermal growth factor receptor
OT  - glioblastoma
OT  - venous thromboembolism
COIS- The authors declare no conflict of interest.
EDAT- 2023/05/26 13:09
MHDA- 2023/05/29 06:41
PMCR- 2023/05/12
CRDT- 2023/05/26 09:34
PHST- 2023/03/21 00:00 [received]
PHST- 2023/04/25 00:00 [revised]
PHST- 2023/05/09 00:00 [accepted]
PHST- 2023/05/29 06:41 [medline]
PHST- 2023/05/26 13:09 [pubmed]
PHST- 2023/05/26 09:34 [entrez]
PHST- 2023/05/12 00:00 [pmc-release]
AID - curroncol30050373 [pii]
AID - curroncol-30-00373 [pii]
AID - 10.3390/curroncol30050373 [doi]
PST - epublish
SO  - Curr Oncol. 2023 May 12;30(5):4946-4956. doi: 10.3390/curroncol30050373.